These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 4155736

  • 21. Evidence of a role for brain monoamines in ethanol dependence.
    Griffiths PJ, Littleton JM, Oritz A, Brownlee G.
    Br J Pharmacol; 1973 Jun; 48(2):354P. PubMed ID: 4147432
    [No Abstract] [Full Text] [Related]

  • 22. Neurochemical mediation of reward: a significant role for dopamine?
    Lippa AS, Antelman SM, Fisher AE, Canfield DR.
    Pharmacol Biochem Behav; 1973 Jun; 1(1):23-8. PubMed ID: 4590600
    [No Abstract] [Full Text] [Related]

  • 23. Effect of L-DOPA analogues in Sidman avoidance performance in mice.
    Thut PD.
    Life Sci; 1977 Aug 01; 21(3):423-31. PubMed ID: 895374
    [No Abstract] [Full Text] [Related]

  • 24. [Interactions of cerebral serotonin and catecholamines].
    Watanabe Y.
    Nihon Yakurigaku Zasshi; 1983 May 01; 81(5):365-83. PubMed ID: 6195056
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L, Deng M, Zhang S, Lu S, Gui X, Fang Y.
    Biomed Pharmacother; 2017 Oct 01; 94():666-678. PubMed ID: 28787702
    [Abstract] [Full Text] [Related]

  • 27. Antagonism by DL-threo-DOPS of the suppression of a conditioned avoidance response induced by a dopamine-beta-hydroxylase inhibitor.
    Ahlenius S, Engel J.
    J Neural Transm; 1973 Oct 01; 34(4):267-77. PubMed ID: 4359658
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of dopamine-beta-hydroxylase inhibitors 1,1-dimethyl-3-phenyl-2-thiourea, fusaric acid and dimethyldithiocarbamate, on the rat brain monoamine content following intraventricular injection of L-dopa.
    Vetulani J, Reichenberg K.
    Biochem Pharmacol; 1973 Jun 01; 22(11):1263-8. PubMed ID: 4727781
    [No Abstract] [Full Text] [Related]

  • 35. [Increase of cerebral dopamine levels by alpha-chymotrypsin in rats pretreated with oxypertine and L-dopa].
    Van den Driessche J, Le Clec'h G, Quiniou P, Linée P, Lacroix P, Patay M, Delamaire J.
    C R Seances Soc Biol Fil; 1974 Jun 01; 168(10-11-12):1393-400. PubMed ID: 4157065
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Release of ( 3 H)noradrenaline and ( 3 H)dopamine from field stimulated cerebral cortex slices. Effect of tyrosine hydroxylase and dopamine- -hydroxylase inhibition.
    Farnebo LO, Hamberger B, Jonsson G.
    J Neurochem; 1971 Dec 01; 18(12):2491-500. PubMed ID: 4400156
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.